These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 15129424

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.
    Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET.
    Prostate; 2001 May 15; 47(3):212-21. PubMed ID: 11351351
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein.
    Dorai T, Gehani N, Katz A.
    Mol Urol; 2000 May 15; 4(1):1-6. PubMed ID: 10851300
    [Abstract] [Full Text] [Related]

  • 4. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM.
    Clin Cancer Res; 2003 Jul 15; 9(7):2587-97. PubMed ID: 12855635
    [Abstract] [Full Text] [Related]

  • 5. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
    Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z, Keller ET.
    Cancer Res; 2005 Dec 01; 65(23):10921-9. PubMed ID: 16322239
    [Abstract] [Full Text] [Related]

  • 6. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis.
    Rubin J, Chung LW, Fan X, Zhu L, Murphy TC, Nanes MS, Rosen CJ.
    Prostate; 2004 Jan 01; 58(1):41-9. PubMed ID: 14673951
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo.
    Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE.
    Prostate; 2001 Jun 01; 47(4):293-303. PubMed ID: 11398177
    [Abstract] [Full Text] [Related]

  • 8. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
    Ling MT, Wang X, Lee DT, Tam PC, Tsao SW, Wong YC.
    Carcinogenesis; 2004 Apr 01; 25(4):517-25. PubMed ID: 14688027
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin.
    Kim JH, Xu C, Keum YS, Reddy B, Conney A, Kong AN.
    Carcinogenesis; 2006 Mar 01; 27(3):475-82. PubMed ID: 16299382
    [Abstract] [Full Text] [Related]

  • 10. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.
    Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM.
    Cancer Res; 2001 Jul 15; 61(14):5652-9. PubMed ID: 11454720
    [Abstract] [Full Text] [Related]

  • 11. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells.
    Levine L, Lucci JA, Pazdrak B, Cheng JZ, Guo YS, Townsend CM, Hellmich MR.
    Cancer Res; 2003 Jul 01; 63(13):3495-502. PubMed ID: 12839933
    [Abstract] [Full Text] [Related]

  • 12. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.
    Hobisch A, Fiechtl M, Sandahl-Sorensen B, Godoy-Tundidor S, Artner-Dworzak E, Ramoner R, Bartsch G, Culig Z.
    Prostate; 2004 Jun 01; 59(4):401-8. PubMed ID: 15065088
    [Abstract] [Full Text] [Related]

  • 13. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Rédini F.
    Bone; 2007 Apr 01; 40(4):981-90. PubMed ID: 17196895
    [Abstract] [Full Text] [Related]

  • 14. Osteoprotegerin in prostate cancer bone metastasis.
    Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL.
    Cancer Res; 2005 Mar 01; 65(5):1710-8. PubMed ID: 15753366
    [Abstract] [Full Text] [Related]

  • 15. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines.
    Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S, Rhim JS.
    Int J Oncol; 2002 Oct 01; 21(4):825-30. PubMed ID: 12239622
    [Abstract] [Full Text] [Related]

  • 16. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW, Baseman A, Assikis V, Zhau HE.
    J Urol; 2005 Jan 01; 173(1):10-20. PubMed ID: 15592017
    [Abstract] [Full Text] [Related]

  • 17. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors.
    Goya M, Miyamoto S, Nagai K, Ohki Y, Nakamura K, Shitara K, Maeda H, Sangai T, Kodama K, Endoh Y, Ishii G, Hasebe T, Yonou H, Hatano T, Ogawa Y, Ochiai A.
    Cancer Res; 2004 Sep 01; 64(17):6252-8. PubMed ID: 15342412
    [Abstract] [Full Text] [Related]

  • 18. Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells.
    Ji C, Cao C, Lu S, Kivlin R, Amaral A, Kouttab N, Yang H, Chu W, Bi Z, Di W, Wan Y.
    Cancer Chemother Pharmacol; 2008 Oct 01; 62(5):857-65. PubMed ID: 18214481
    [Abstract] [Full Text] [Related]

  • 19. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR.
    Chen A, Xu J.
    Am J Physiol Gastrointest Liver Physiol; 2005 Mar 01; 288(3):G447-56. PubMed ID: 15486348
    [Abstract] [Full Text] [Related]

  • 20. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
    Yonou H, Kanomata N, Goya M, Kamijo T, Yokose T, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A.
    Cancer Res; 2003 May 01; 63(9):2096-102. PubMed ID: 12727825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.